The reciprocity between radiotherapy and cancer immunotherapy

Yifan Wang, Zhi Gang Liu, Hengfeng Yuan, Weiye Deng, Jing Li, Yuhui Huang, Y S Betty Kim, Michael D. Story, Wen Jiang

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The clinical success of immune checkpoint inhibitors in treating metastatic and refractory cancers has generated significant interest in investigating their role in treating locally advanced diseases, thus requiring them to be combined with standard treatments in the hope of producing synergistic antitumor responses. Radiotherapy, in particular, has long been hypothesized to have actions complementary to those of immune checkpoint blockade, and a growing body of evidence indicates that cancer immunotherapy may also have radiosensitizing effects, which would provide unique benefit for locoregional treatments. Recent studies have demonstrated that when immune cells are activated by immunotherapeutics, they can reprogram the tumor microenvironment in ways that may potentially increase the radiosensitivity of the tumor. In this review, we highlight the evidence that supports reciprocal interactions between cancer immunotherapy and radiotherapy, where in addition to the traditional notion that radiation serves to enhance the activation of antitumor immunity, an alternative scenario also exists in which T-cell activation by cancer immunotherapy may sensitize tumors to radiation treatment through mechanisms that include normalization of the tumor vasculature and tissue hypoxia. We describe the empirical observations from preclinical models that support such effects and discuss their implications for future research and trial design.

Original languageEnglish (US)
Pages (from-to)1709-1717
Number of pages9
JournalClinical Cancer Research
Volume25
Issue number6
DOIs
StatePublished - Jan 1 2019

Fingerprint

Immunotherapy
Radiotherapy
Neoplasms
Radiation
Radiation-Sensitizing Agents
Tumor Microenvironment
Radiation Tolerance
Immunity
Research Design
Therapeutics
T-Lymphocytes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wang, Y., Liu, Z. G., Yuan, H., Deng, W., Li, J., Huang, Y., ... Jiang, W. (2019). The reciprocity between radiotherapy and cancer immunotherapy. Clinical Cancer Research, 25(6), 1709-1717. https://doi.org/10.1158/1078-0432.CCR-18-2581

The reciprocity between radiotherapy and cancer immunotherapy. / Wang, Yifan; Liu, Zhi Gang; Yuan, Hengfeng; Deng, Weiye; Li, Jing; Huang, Yuhui; Kim, Y S Betty; Story, Michael D.; Jiang, Wen.

In: Clinical Cancer Research, Vol. 25, No. 6, 01.01.2019, p. 1709-1717.

Research output: Contribution to journalReview article

Wang, Y, Liu, ZG, Yuan, H, Deng, W, Li, J, Huang, Y, Kim, YSB, Story, MD & Jiang, W 2019, 'The reciprocity between radiotherapy and cancer immunotherapy', Clinical Cancer Research, vol. 25, no. 6, pp. 1709-1717. https://doi.org/10.1158/1078-0432.CCR-18-2581
Wang, Yifan ; Liu, Zhi Gang ; Yuan, Hengfeng ; Deng, Weiye ; Li, Jing ; Huang, Yuhui ; Kim, Y S Betty ; Story, Michael D. ; Jiang, Wen. / The reciprocity between radiotherapy and cancer immunotherapy. In: Clinical Cancer Research. 2019 ; Vol. 25, No. 6. pp. 1709-1717.
@article{3f1eb02449e246cdbe1678100a90f115,
title = "The reciprocity between radiotherapy and cancer immunotherapy",
abstract = "The clinical success of immune checkpoint inhibitors in treating metastatic and refractory cancers has generated significant interest in investigating their role in treating locally advanced diseases, thus requiring them to be combined with standard treatments in the hope of producing synergistic antitumor responses. Radiotherapy, in particular, has long been hypothesized to have actions complementary to those of immune checkpoint blockade, and a growing body of evidence indicates that cancer immunotherapy may also have radiosensitizing effects, which would provide unique benefit for locoregional treatments. Recent studies have demonstrated that when immune cells are activated by immunotherapeutics, they can reprogram the tumor microenvironment in ways that may potentially increase the radiosensitivity of the tumor. In this review, we highlight the evidence that supports reciprocal interactions between cancer immunotherapy and radiotherapy, where in addition to the traditional notion that radiation serves to enhance the activation of antitumor immunity, an alternative scenario also exists in which T-cell activation by cancer immunotherapy may sensitize tumors to radiation treatment through mechanisms that include normalization of the tumor vasculature and tissue hypoxia. We describe the empirical observations from preclinical models that support such effects and discuss their implications for future research and trial design.",
author = "Yifan Wang and Liu, {Zhi Gang} and Hengfeng Yuan and Weiye Deng and Jing Li and Yuhui Huang and Kim, {Y S Betty} and Story, {Michael D.} and Wen Jiang",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/1078-0432.CCR-18-2581",
language = "English (US)",
volume = "25",
pages = "1709--1717",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - The reciprocity between radiotherapy and cancer immunotherapy

AU - Wang, Yifan

AU - Liu, Zhi Gang

AU - Yuan, Hengfeng

AU - Deng, Weiye

AU - Li, Jing

AU - Huang, Yuhui

AU - Kim, Y S Betty

AU - Story, Michael D.

AU - Jiang, Wen

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The clinical success of immune checkpoint inhibitors in treating metastatic and refractory cancers has generated significant interest in investigating their role in treating locally advanced diseases, thus requiring them to be combined with standard treatments in the hope of producing synergistic antitumor responses. Radiotherapy, in particular, has long been hypothesized to have actions complementary to those of immune checkpoint blockade, and a growing body of evidence indicates that cancer immunotherapy may also have radiosensitizing effects, which would provide unique benefit for locoregional treatments. Recent studies have demonstrated that when immune cells are activated by immunotherapeutics, they can reprogram the tumor microenvironment in ways that may potentially increase the radiosensitivity of the tumor. In this review, we highlight the evidence that supports reciprocal interactions between cancer immunotherapy and radiotherapy, where in addition to the traditional notion that radiation serves to enhance the activation of antitumor immunity, an alternative scenario also exists in which T-cell activation by cancer immunotherapy may sensitize tumors to radiation treatment through mechanisms that include normalization of the tumor vasculature and tissue hypoxia. We describe the empirical observations from preclinical models that support such effects and discuss their implications for future research and trial design.

AB - The clinical success of immune checkpoint inhibitors in treating metastatic and refractory cancers has generated significant interest in investigating their role in treating locally advanced diseases, thus requiring them to be combined with standard treatments in the hope of producing synergistic antitumor responses. Radiotherapy, in particular, has long been hypothesized to have actions complementary to those of immune checkpoint blockade, and a growing body of evidence indicates that cancer immunotherapy may also have radiosensitizing effects, which would provide unique benefit for locoregional treatments. Recent studies have demonstrated that when immune cells are activated by immunotherapeutics, they can reprogram the tumor microenvironment in ways that may potentially increase the radiosensitivity of the tumor. In this review, we highlight the evidence that supports reciprocal interactions between cancer immunotherapy and radiotherapy, where in addition to the traditional notion that radiation serves to enhance the activation of antitumor immunity, an alternative scenario also exists in which T-cell activation by cancer immunotherapy may sensitize tumors to radiation treatment through mechanisms that include normalization of the tumor vasculature and tissue hypoxia. We describe the empirical observations from preclinical models that support such effects and discuss their implications for future research and trial design.

UR - http://www.scopus.com/inward/record.url?scp=85062967691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062967691&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-2581

DO - 10.1158/1078-0432.CCR-18-2581

M3 - Review article

VL - 25

SP - 1709

EP - 1717

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -